$BWAY

Roth Yiftach sold 2,000 shares of BWAY

Roth Yiftach (Chief Scientist) sold 2,000 shares of Brainsway Ltd. (BWAY) on 2026-06-02.

Original reporting
SEC EDGAR · Roth Yiftach
Published Jun 3, 2026, 8:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BWAY
Neutral
medium confidence
Mentioned
$BWAY
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BWAYNeutralLow
01

Why it matters

Because the filing does not disclose execution price or total value, it provides limited actionable information about valuation or near-term catalysts.

02

Market read

Insider selling disclosure may slightly affect sentiment, but lacks new fundamental data and is unlikely to drive a sustained repricing alone.

03

What to watch

The sale was not stated as part of a 10b5-1 plan, but the absence of trade price/value limits inference about insider conviction.

Relevance 6/10Novelty 3/10Timing: Filed 2026-06-03 after the sale dated 2026-06-02.

Background

This is an SEC Form 4 insider transaction: Roth Yiftach (Chief Scientist) reported an open-market sale of 2,000 shares in Brainsway Ltd.

Company-level read

Ticker impact

$BWAYNeutralMedium confidence
Context

Brainsway insider Roth Yiftach (Chief Scientist) sold 2,000 shares via an open-market Form 4 disclosure.

Expected impact

Low near-term impact; any reaction is likely limited and sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider sales are common and this one lacks disclosed execution price/value and is not tied to a new corporate event.

Market effects

No clear sector read-through from a single insider sale.

None indicated.

None indicated.

Counterpoint

Even without disclosed price/value, repeated insider selling can precede weaker performance expectations.

Key entities

  • Brainsway Ltd.

    Subject of the Form 4 insider sale disclosure.

  • Roth Yiftach

    Chief Scientist who sold 2,000 shares; sale reported via Form 4.

Related articles